EE200200227A - Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid - Google Patents

Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid

Info

Publication number
EE200200227A
EE200200227A EEP200200227A EEP200200227A EE200200227A EE 200200227 A EE200200227 A EE 200200227A EE P200200227 A EEP200200227 A EE P200200227A EE P200200227 A EEP200200227 A EE P200200227A EE 200200227 A EE200200227 A EE 200200227A
Authority
EE
Estonia
Prior art keywords
crystals
type
sodium hydrogen
hydrogen ion
ion inhibitor
Prior art date
Application number
EEP200200227A
Other languages
English (en)
Estonian (et)
Inventor
Robinson Brostrom Lyle
Joseph Connolly Terrence
Jane Li Zheng
Lee Orrill Susan
Kiritkumar Shah Bharat
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200227A publication Critical patent/EE200200227A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200227A 1999-10-29 2000-10-09 Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid EE200200227A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (1)

Publication Number Publication Date
EE200200227A true EE200200227A (et) 2003-06-16

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200227A EE200200227A (et) 1999-10-29 2000-10-09 Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid

Country Status (44)

Country Link
EP (1) EP1224179B1 (sh)
JP (1) JP2003512455A (sh)
KR (1) KR100464526B1 (sh)
CN (2) CN1205205C (sh)
AP (1) AP2002002493A0 (sh)
AR (1) AR029402A1 (sh)
AT (1) ATE271047T1 (sh)
AU (1) AU778573B2 (sh)
BG (1) BG106729A (sh)
BR (1) BR0015275A (sh)
CA (1) CA2389020A1 (sh)
CO (1) CO5271714A1 (sh)
CZ (1) CZ20021332A3 (sh)
DE (1) DE60012208T2 (sh)
DK (1) DK1224179T3 (sh)
DZ (1) DZ3463A1 (sh)
EA (1) EA004937B1 (sh)
EE (1) EE200200227A (sh)
ES (1) ES2222923T3 (sh)
GE (1) GEP20043222B (sh)
GT (1) GT200000180A (sh)
HK (1) HK1048472B (sh)
HR (1) HRP20020366B1 (sh)
HU (1) HUP0204009A3 (sh)
IL (1) IL148581A0 (sh)
IS (1) IS6302A (sh)
MA (1) MA26840A1 (sh)
MX (1) MXPA02004358A (sh)
NO (1) NO20021821D0 (sh)
NZ (1) NZ517738A (sh)
OA (1) OA12080A (sh)
PA (1) PA8505501A1 (sh)
PE (1) PE20010764A1 (sh)
PL (1) PL354869A1 (sh)
PT (1) PT1224179E (sh)
SI (1) SI1224179T1 (sh)
SK (1) SK5312002A3 (sh)
SV (1) SV2002000209A (sh)
TN (1) TNSN00210A1 (sh)
TR (1) TR200201167T2 (sh)
UA (1) UA72002C2 (sh)
WO (1) WO2001030759A2 (sh)
YU (1) YU31502A (sh)
ZA (1) ZA200203295B (sh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU51903A (sh) * 2001-01-31 2006-05-25 Pfizer Products Inc. Enolati inhibitora izmene natrijum-vodonik tipa-1
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083004A (ko) * 1998-02-27 2003-10-23 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
WO2001030759A2 (en) 2001-05-03
YU31502A (sh) 2004-12-31
WO2001030759A3 (en) 2001-09-13
EP1224179A2 (en) 2002-07-24
MXPA02004358A (es) 2002-11-07
SK5312002A3 (en) 2003-01-09
HUP0204009A2 (hu) 2003-03-28
JP2003512455A (ja) 2003-04-02
NO20021821L (no) 2002-04-18
BG106729A (bg) 2002-12-29
NO20021821D0 (no) 2002-04-18
CZ20021332A3 (cs) 2002-10-16
PT1224179E (pt) 2004-10-29
AU7441500A (en) 2001-05-08
IS6302A (is) 2002-03-15
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
HUP0204009A3 (en) 2004-07-28
AU778573B2 (en) 2004-12-09
DK1224179T3 (da) 2004-10-25
CN1636991A (zh) 2005-07-13
OA12080A (en) 2003-08-25
CA2389020A1 (en) 2001-05-03
SI1224179T1 (en) 2004-10-31
GT200000180A (es) 2002-04-11
ZA200203295B (en) 2003-06-25
KR20020040918A (ko) 2002-05-30
AP2002002493A0 (en) 2002-06-30
ES2222923T3 (es) 2005-02-16
HRP20020366A2 (en) 2004-02-29
DZ3463A1 (fr) 2001-05-03
ATE271047T1 (de) 2004-07-15
CO5271714A1 (es) 2003-04-30
TR200201167T2 (tr) 2002-08-21
MA26840A1 (fr) 2004-12-20
CN1205205C (zh) 2005-06-08
KR100464526B1 (ko) 2005-01-03
BR0015275A (pt) 2002-07-16
EA200200416A1 (ru) 2002-10-31
EP1224179B1 (en) 2004-07-14
IL148581A0 (en) 2002-09-12
DE60012208D1 (de) 2004-08-19
HK1048472B (zh) 2005-09-16
SV2002000209A (es) 2002-07-16
UA72002C2 (en) 2005-01-17
PL354869A1 (en) 2004-03-08
HRP20020366B1 (en) 2005-04-30
PA8505501A1 (es) 2003-09-05
CN1384829A (zh) 2002-12-11
EA004937B1 (ru) 2004-10-28
TNSN00210A1 (fr) 2005-11-10
HK1048472A1 (en) 2003-04-04
GEP20043222B (en) 2004-04-26
NZ517738A (en) 2005-06-24
DE60012208T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE330935T1 (de) Inhibitoren der alpha4 vermittelten zelladhäsion
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
ATE258918T1 (de) Kristallform alpha des perindopril-tert- butylaminsalzes
ATE245142T1 (de) No-synthase inhibitoren
FI980033A0 (fi) Solujen kiinnittymisen inhibiittoreita
DK1114051T3 (da) Inhibitorer for p38
IS2071B (is) Ný 3-arýl-2-hýdroxýprópíonsýruafleiða (I)
ID26925A (id) Inhibitor-inhibitor metalloproteasa hidroksimata pirrolidina yang tersubstitusi
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
ID28208A (id) Konstruksi penegang pengapung
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
ID25901A (id) Proses pembuatan 4-aminometil-pirolidin-3-on terlindung
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DK1082575T3 (da) Vandfri krystaller
EE200200227A (et) Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid
DE69824279D1 (de) Stabilisiertes Natriumcarbonat-Peroxyhydrat
IT1317603B1 (it) Disposizione di guarnizioni per custodia
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
FI970314A (fi) Stabiloitu natriumkarbonaattiperoksihydraatti
DE69905397D1 (de) Selektive inhibitoren des mmp-12